ANK3 (Ankyrin 3)

Repurposed drug candidates were then predicted via signature-based prioritization and evaluated using molecular docking simulations, revealing six promising compounds for GBM (vandetanib, capecitabine, melatonin, agomelatine, ramelteon, and tasimelteon) and one for LGG (ambroxol). This study demonstrates the utility of combining class-balancing, feature selection, and drug repurposing pipelines to uncover clinically relevant glioma biomarkers and therapeutic candidates, thus providing a computational foundation for future experimental and translational validation in these brain cancers and neuro-oncology.

We conclude that GenMorw, with its novel gene-patient score mechanism, offers a significant advance in cancer driver gene discovery by capturing both population-wide and patient-specific network signals, thereby improving predictive power and enabling deeper insights into cancer heterogeneity.

Knockdown of RBM8A promoted RS of ANK3-TV4 and upregulated its expression. We investigate the role of RS in HCC, providing a novel therapeutic perspective and identifying potential targets for intervention.

Finally, a decrease in ANK3 expression was confirmed in ccRCC tissues (grades I and II) compared to adjacent normal tissues. These findings suggest that ANK3 acts as a potential modulator of cell adhesion and cytoskeleton remodeling in ccRCC and may represent a promising therapeutic target for this malignancy.

These findings highlight magnesium homeostasis as a regulator of tumor progression and immunity, with MHS serving as a prognostic biomarker. Targeting magnesium pathways may offer novel therapeutic strategies, warranting further clinical validation to advance personalized cancer therapies.

This activity involves governing inflammatory responses alongside cellular proliferation, migration, and differentiation processes. These findings offer a theoretical foundation supporting paeonol's potential clinical utility in cervical cancer management.

These findings reveal a previously unrecognized relationship between Macro_SPP1high cells and HSPA1Ahigh/HSPA1Bhigh T cells in driving CCLM progression, suggesting a potential synergistic therapeutic approach that could boost immune checkpoint treatment efficacy in patients with CCLM.

We herein describe an original case of subacute-onset BAD/FAS with evidence of CSF inflammatory changes, autoantibodies of unknown significance, and simultaneous diagnosis of prostate cancer suggesting a possible paraneoplastic neurological syndrome (PNS). The outcome was remarkably favorable after hormonotherapy. Even in the absence of usual onconeural antibodies, MND may be encountered among PNS, and their prognosis is not always poor.

ATP1A1 is proposed as a promising therapeutic target, with Emodinanthrone emerging as a novel drug candidate. These findings contribute to the advancement of personalized treatment strategies for KIRC patients.

A new JAK-STAT related CRC prognostic model was constructed and validated, which possessed an underlying predictive potential for CRC patients' prognosis and could potentially enhance tailored guidance for immunotherapy.

Several MRGs are aberrantly expressed in KIRC, from which we screened 23 genes and constructed a MRGs prognostic risk model that can effectively predict the prognosis of KIRC patients and provide a new foundation for personalised diagnosis and treatment of KIRC.

Unbiased translatomic profiling reveals potential compensatory machineries. These results highlight the functions of glial AnkG in maintaining proper axoglial interactions throughout aging and suggest a contribution of glial AnkG to neuropsychiatric disorders.